ATAI
preliminary data subject to change sedation or dizziness confirms safety profile a both i | ATAI
Company
Deck Type
Sector
Industry
Deck date
March 2023
Slide
23 of 31
Similar slides by ATAI
See diffirences between slides (animation)
Investor Presentation
October 2023
safe and well tolerated with sedation comparable to placebo and consistent with the results on alpha power phase study detailed safety data | ATAI
Investor Presentation
April 2023
sedation or dizziness confirms safety profile | ATAI
Investor Presentation
February 2023
preliminary data subject to change sedation or dizziness confirms safety profile a both i | ATAI
Investor Presentation
January 2023
preliminary data subject to change sedation or dizziness confirms safety profile a both i | ATAI
Related slides by other companies
Adagio Therapeutics
Results
June 2022
safety data and conclusions | Adagio Therapeutics
Arbutus Biopharma
Results
November 2022
preliminary phase a triple combination data | Arbutus Biopharma
Fusion Pharmaceuticals
Investor Presentation
August 2023
phase trial preliminary safety summary | Fusion Pharmaceuticals
Fusion Pharmaceuticals
Investor Presentation
November 2023
phase trial preliminary safety summary | Fusion Pharmaceuticals
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io